Gilbert S. Mott, Jr.

President and Chief Executive Officer

Mr. Mott is a pharmaceutical and medical device executive with a 37 year career focus on respiratory pharmaceuticals and medical devices. Mr. Mott is the cofounder President and Chief Executive Officer of Concentrx Pharmaceuticals, Inc. Formerly, Mr. Mott was the founder, President, and CEO of Respirics, Inc., an inhaled pharmaceutical development company based in Raleigh, NC.

Earlier in his career, Mr. Mott served as Vice President of US Marketing for Respiratory products at Glaxo, Inc., and was later VP of Managed Markets and lastly Vice President of Managed Care at Glaxo. In 1995, Mr. Mott joined Enact Health Management Systems, later, in Mountain View, CA, makers of AirWatch, the first online personal health information system for asthmatic patients.

Mr. Mott is a graduate of the University of Miami and studied marketing at the University of California Los Angeles Anderson School of Management.



Eric C. Richardson, ME

Sr. Vice President and Chief Operating Officer

Mr. Richardson is a mechanical engineer with 25 years of experience, 16 years focused on respiratory drug delivery devices. Mr. Richardson is the cofounder Sr. Vice President and Chief Operating Officer of Concentrx Pharmaceuticals, Inc. Formerly, Mr. Richardson worked for 3M Riker Laboratories while attending University and worked as a Product Development Engineer for Bespak Ltd and Director of Product Development and Manufacturing for Respirics, Inc. in North Carolina before forming his consulting firm Syphase, LLC in 2010.

Mr. Richardson is a leading design and manufacturing engineer and the inventor of the Halix™ Unit Dose Disposable – Dry Powder Inhaler. 

Mr. Richardson is a graduate of California State University Chico.

W. James Alexander, M.D., M.PH.
Director, Medical and Regulatory Affairs

​Dr. Alexander is an internist and infectious disease specialist. Begining in 1987 Dr. Alexander supervised US clinical development of antibacterials and antivirals at Beecham Laboratories. Dr. Alexander joined Glaxo in 1990 and played a key role in the US Phase 3 clinical studies of Serevent for the treatment of asthma; presenting pivotal data to an FDA advisory committee in support of approval. After the US launch of Serevent, Glaxo named Dr. Alexander as the international clinical leader for lamivudine as a treatment for HIV infection. Dr. Alexanders expertise was next recognized by his appointment as head of Glaxo (US) Pharmacovigilance in 1994 and, in 1996, he was named worldwide head of pharmacovigilance for GlaxoWellcome. After leaving GlaxoWellcome in 1998, he has worked within and for clinical research organizations (CROs) and as an independent medical consultant assisting small and large pharmaceutical companies in advancing clinical development programs in respiratory, neurology, infectious disease, and oncology indications. 

Dr. Alexander completed internal medicine training at the University of Alabama in Birmingham and was an NIH-funded (virology) Fellow in Infectious Diseases.